Cell News and Research

RSS

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

ArQule, Inc. today announced that ARQ 197, when used in combination with erlotinib, demonstrated a 66% improvement in median Progression-Free Survival in patients with advanced, refractory non-small cell lung cancer.

31 Mar 2010

T-cell cytolytic activity may be effective in clearing HBV infection

Co-infection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) poses a treatment challenge. In Western Europe and the United States, chronic HBV infection has been found in 6%󈝺% of HIV-positive patients and this co-infection is well known to be associated with increased liver-related morbidity and mortality. However, factors associated with HBV surface antigen (HbsAg) loss in HIV and HBV co-infected patients remain unclear.

31 Mar 2010

National Doctors' Day: St. Jude Children's Research Hospital honors physicians and staff

As physicians nationwide are acknowledged for their talent, sacrifice and courage on National Doctors' Day, St. Jude Children's Research Hospital honors its more than 230 staff and consulting physicians who strive to fulfill the hospital's mission each day.

31 Mar 2010

Cryo-Cell International, MOSI partner to develop educational exhibit on stem cells and regenerative science

Cryo-Cell International Inc., a global leader of innovative stem cell solutions and stem cell cryopreservation services, today announced plans to partner with Museum of Science & Industry (MOSI) in the development and launch of an interactive educational exhibit on stem cells and regenerative science. Cryo-Cell is one of the most established private family cord blood banks and is a pioneer in the stem cell industry.

31 Mar 2010

Panel of experts endorse effectiveness of Mirasol PRT System for preventing GVHD

CaridianBCT, a leading global provider of technology, products and services in the blood banking, transfusion medicine and cell therapy industries, today announced that a panel of medical and scientific experts have endorsed the effectiveness of the Mirasol® Pathogen Reduction Technology System for replacing gamma irradiation, the current standard of care for preventing transfusion-related Graft vs. Host Disease in platelet recipients.

31 Mar 2010

SCYNEXIS presents overview of novel cyclophilin inhibitor at Hepatitis C Conference

Drug discovery company, SCYNEXIS, Inc. announced today that management will present an overview on the Company's lead anti-hepatitis C virus (HCV) candidate, SCY-635, at the upcoming Canaccord Adams' Hepatitis C Conference on Thursday, April 1, 2010 at 11:15 am ET at the Peninsula Hotel in New York City.

31 Mar 2010

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.

31 Mar 2010

Bioheart presents cutting edge therapies at 2010 Translational Regenerative Medicine Forum

Bioheart, Inc., announced today that Dr. Karl E. Groth, the Company's Chairman and CEO will speak at the 2010 Translational Regenerative Medicine Forum in Winston-Salem, North Carolina, on April 8. Dr. Groth will discuss Bioheart's cell therapies for Congestive Heart Failure.

31 Mar 2010

Plant-based system could help improve lives of hemophilic patients

Hemophilia, a disease linked with legends of European monarchs, frail heirs and one flamboyant charlatan called Rasputin, still afflicts many people today.

31 Mar 2010

BioNanomatrix awarded patent covering nanochannel arrays for high-throughput macromolecular analysis

BioNanomatrix, Inc., a developer of breakthrough single-molecule genomic analysis technology, today announced the issuance of U.S. patent 7,670,770 for nanochannel arrays that enable high-throughput macromolecular analysis. Also disclosed are methods of preparing nanochannel array chips, methods of analyzing macromolecules such as entire strands of genomic DNA, and systems for implementing these methods.

31 Mar 2010

BIO pleased with Court's dismissal of claims over patenting gene-based inventions

“As explained in the ruling yesterday, the District Court's determination is only a preliminary step in the legal process that does not affect how the U.S. Patent and Trademark Office (PTO) evaluates patent applications relating to DNA-based inventions.”

31 Mar 2010

Researcher explores the use of Chinese wolfberries to improve vision deficiencies

A Kansas State University researcher is exploring the use of Chinese wolfberries to improve vision deficiencies that are common for type-2 diabetics.

31 Mar 2010

$Notch pathway could aid treatment of osteoporosis, fractures and arthritis$

Notch pathway could aid treatment of osteoporosis, fractures and arthritis

Scientists seeking new ways to fight maladies ranging from arthritis and osteoporosis to broken bones that won't heal have cleared a formidable hurdle, pinpointing and controlling a key molecular player to keep stem cells in a sort of extended infancy.

31 Mar 2010

AAN awards Cedars-Sinai researcher 2010 Sheila Essey Award for ALS research

The American Academy of Neurology (AAN) is awarding the 2010 Sheila Essey Award-An Award for ALS Research to Clive Svendsen, PhD, with the Cedars-Sinai Regenerative Medicine Institute in Los Angeles, CA. Svendsen will receive the award during the AAN's 62nd Annual Meeting in Toronto, held April 10 through April 17, 2010.

31 Mar 2010

Prevalence of head and neck cancer linked to human papillomavirus

Rates of oropharangeal cancer have increased by around 50 per cent in the last 20 years, according to a report in the British Medical Journal.

31 Mar 2010

Cell Therapeutics agrees to sell $20M of Series 4 Preferred Stock and warrants to institutional investors

Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell $20 million of shares of its Series 4 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to three institutional investors.

31 Mar 2010

PolyMedix completes Phase 1B clinical study with PMX-30063 defensin-mimetic antibiotic

PolyMedix, Inc., an emerging bio-technology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B clinical study with its novel defensin-mimetic antibiotic, PMX-30063. The data from the study demonstrate that administration of multiple doses of PMX-30063 are safe and well-tolerated at dose levels which showed bactericidal activity in blood samples drawn from subjects in the study.

31 Mar 2010

Dr. Ingmar Bruns selected as seventh recipient of EHA-ASH Research Exchange Award

The European Hematology Association and the American Society of Hematology have selected Ingmar Bruns, MD, as the seventh recipient of the EHA-ASH Research Exchange Award, which serves to strengthen ties between North American and European scientific communities.

31 Mar 2010

BioSante Pharmaceuticals completes Azur Pharma Elestrin royalty buydown

BioSante Pharmaceuticals, Inc. today announced the successful completion of the Azur Pharma Elestrin royalty buydown, and financial results for the year ended December 31, 2009.

31 Mar 2010

Eisai seeks simultaneous approval of eribulin mesylate in U.S., EU and Japan

Eisai Inc. today announced that it has submitted simultaneous regulatory applications for approval of eribulin mesylate (also known as E7389) for the treatment of locally advanced or metastatic breast cancer to agencies in Japan, the United States and the European Union (EU). Eribulin, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai.

31 Mar 2010

Cell News and Research

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

T-cell cytolytic activity may be effective in clearing HBV infection

National Doctors' Day: St. Jude Children's Research Hospital honors physicians and staff

Cryo-Cell International, MOSI partner to develop educational exhibit on stem cells and regenerative science

Panel of experts endorse effectiveness of Mirasol PRT System for preventing GVHD

SCYNEXIS presents overview of novel cyclophilin inhibitor at Hepatitis C Conference

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Bioheart presents cutting edge therapies at 2010 Translational Regenerative Medicine Forum

Plant-based system could help improve lives of hemophilic patients

BioNanomatrix awarded patent covering nanochannel arrays for high-throughput macromolecular analysis

BIO pleased with Court's dismissal of claims over patenting gene-based inventions

Researcher explores the use of Chinese wolfberries to improve vision deficiencies

Notch pathway could aid treatment of osteoporosis, fractures and arthritis

AAN awards Cedars-Sinai researcher 2010 Sheila Essey Award for ALS research

Prevalence of head and neck cancer linked to human papillomavirus

Cell Therapeutics agrees to sell $20M of Series 4 Preferred Stock and warrants to institutional investors

PolyMedix completes Phase 1B clinical study with PMX-30063 defensin-mimetic antibiotic

Dr. Ingmar Bruns selected as seventh recipient of EHA-ASH Research Exchange Award

BioSante Pharmaceuticals completes Azur Pharma Elestrin royalty buydown

Eisai seeks simultaneous approval of eribulin mesylate in U.S., EU and Japan

Industry focus eBook - Cell and gene therapy (2nd edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo